Eli Lilly lands in San Jose the week Foundayo data dominates ADA

Eli Lilly flew from Boston to San Jose on the evening of June 17, touching down just before 8:30 p.m. Pacific time after a 5-hour, 50-minute crossing. The Gulfstream G500, tail N307EL, departed Logan International and climbed to 45,025 feet for the transcontinental leg, a route the company’s flight department has flown multiple times this month.

The trip comes the same week the American Diabetes Association’s 86th Scientific Sessions wrapped in Boston, where Eli Lilly presented Phase 3 results showing its new oral GLP-1 Foundayo (orforglipron) outperformed oral semaglutide on both A1C reduction and weight loss, per data released by the company and covered by BioSpace and CNBC. The FDA approved Foundayo for obesity in April, and the company is now preparing to submit a type 2 diabetes label expansion. The San Jose arrival may signal meetings with Bay Area partners or investors tied to the company’s $10 billion-plus M&A push this year, as Lilly’s head of corporate development told CNBC it is using GLP-1 revenue to fund larger deals.

The flight fits a pattern of frequent owner travel: the same G500 flew from Indianapolis to Boston on June 16, and from Massachusetts to Pennsylvania earlier in the week. Eli Lilly’s home base remains Indianapolis, but the aircraft logged eight flights in the prior nine days, suggesting a busy second-quarter roadshow for a company that just raised full-year revenue guidance by $2 billion on the back of Mounjaro’s $8.7 billion first quarter.